Literature DB >> 29941546

Evaluation of liver test abnormalities in a patient-centered medical home: do liver test patterns matter?

Andrew D Schreiner1, William P Moran1, Jingwen Zhang1, Elizabeth B Kirkland1, Marc E Heincelman1, Samuel O Schumann Iii1, Patrick D Mauldin1, Don C Rockey1.   

Abstract

Abnormal liver tests are extremely common in clinical practice, present with varying patterns and degrees of elevation, and can signal liver injury from a variety of causes. Responding to these abnormalities requires complex medical decision-making and merits investigation in primary care. This retrospective study investigates the association of patterns of liver test abnormality with follow-up in primary care. Using administrative data, this study includes patients with abnormal liver tests seen between 2007 and 2016 in a patient-centered medical home. Liver tests examined include serum bilirubin, aspartate aminotransferase, alanine aminotransferase, and alkaline phosphatase. Patients entered the cohort on the first liver test elevation. The outcome examined was completion of repeat testing, and the proportions of patients without follow-up were compared by patterns of index abnormality. 9545 patients met the inclusion criteria. Of these, 6155 (64.5%) possessed one liver test abnormality and 3390 (35.5%) possessed multiple abnormalities on index testing. Overall 1119 (11.7%) patients did not have repeat testing performed during the study period. A greater proportion of patients with lone abnormalities lacked repeat testing compared with those patients with multiple abnormalities. Differences in repeat testing appeared when comparing clinical patterns of abnormality, with higher proportions of follow-up in patients with testing suggestive of cholestasis. Over 11% of patients with abnormal liver tests did not undergo repeat testing during the study period. Repeat testing occurred more often in patients with multiple abnormalities and in clinical patterns suggestive of cholestasis. This study highlights a potential opportunity to improve quality of care. © American Federation for Medical Research (unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Keywords:  diagnostic tests, routine; liver diseases; medical research; primary health care

Mesh:

Substances:

Year:  2018        PMID: 29941546      PMCID: PMC6482948          DOI: 10.1136/jim-2018-000788

Source DB:  PubMed          Journal:  J Investig Med        ISSN: 1081-5589            Impact factor:   2.895


  15 in total

Review 1.  Evaluation of abnormal liver-enzyme results in asymptomatic patients.

Authors:  D S Pratt; M M Kaplan
Journal:  N Engl J Med       Date:  2000-04-27       Impact factor: 91.245

Review 2.  Diagnosis and monitoring of hepatic injury. I. Performance characteristics of laboratory tests.

Authors:  D R Dufour; J A Lott; F S Nolte; D R Gretch; R S Koff; L B Seeff
Journal:  Clin Chem       Date:  2000-12       Impact factor: 8.327

Review 3.  Evaluating asymptomatic patients with mildly elevated liver enzymes.

Authors:  Z M Younossi
Journal:  Cleve Clin J Med       Date:  1998-03       Impact factor: 2.321

4.  ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries.

Authors:  Paul Y Kwo; Stanley M Cohen; Joseph K Lim
Journal:  Am J Gastroenterol       Date:  2016-12-20       Impact factor: 10.864

5.  Extensive testing or focused testing of patients with elevated liver enzymes.

Authors:  Elliot B Tapper; Sameer D Saini; Neil Sengupta
Journal:  J Hepatol       Date:  2016-10-04       Impact factor: 25.083

6.  Genetic variation in bilirubin UPD-glucuronosyltransferase gene promoter and Gilbert's syndrome.

Authors:  G Monaghan; M Ryan; R Seddon; R Hume; B Burchell
Journal:  Lancet       Date:  1996-03-02       Impact factor: 79.321

7.  Development of a decision support tool for primary care management of patients with abnormal liver function tests without clinically apparent liver disease: a record-linkage population cohort study and decision analysis (ALFIE).

Authors:  P T Donnan; D McLernon; J F Dillon; S Ryder; P Roderick; F Sullivan; W Rosenberg
Journal:  Health Technol Assess       Date:  2009-04       Impact factor: 4.014

8.  Use of Hy's law and a new composite algorithm to predict acute liver failure in patients with drug-induced liver injury.

Authors:  Mercedes Robles-Diaz; M Isabel Lucena; Neil Kaplowitz; Camilla Stephens; Inmaculada Medina-Cáliz; Andres González-Jimenez; Eugenia Ulzurrun; Ana F Gonzalez; M Carmen Fernandez; Manuel Romero-Gómez; Miguel Jimenez-Perez; Miguel Bruguera; Martín Prieto; Fernando Bessone; Nelia Hernandez; Marco Arrese; Raúl J Andrade
Journal:  Gastroenterology       Date:  2014-04-01       Impact factor: 22.682

Review 9.  Evaluation of abnormal liver function tests.

Authors:  Swastik Agrawal; Radha K Dhiman; Jimmy K Limdi
Journal:  Postgrad Med J       Date:  2016-02-03       Impact factor: 2.401

10.  Development of a decision support tool to facilitate primary care management of patients with abnormal liver function tests without clinically apparent liver disease [HTA03/38/02]. Abnormal Liver Function Investigations Evaluation (ALFIE).

Authors:  Peter T Donnan; David McLernon; Douglas Steinke; Stephen Ryder; Paul Roderick; Frank M Sullivan; William Rosenberg; John F Dillon
Journal:  BMC Health Serv Res       Date:  2007-04-16       Impact factor: 2.655

View more
  3 in total

1.  Abnormal Liver Enzymes.

Authors:  Shih-Wei Lai
Journal:  J Gen Intern Med       Date:  2019-09       Impact factor: 5.128

2.  When Do Clinicians Follow-up Abnormal Liver Tests in Primary Care?

Authors:  Andrew D Schreiner; John Bian; Jingwen Zhang; Elizabeth B Kirkland; Marc E Heincelman; Samuel O Schumann; Patrick D Mauldin; William P Moran; Don C Rockey
Journal:  Am J Med Sci       Date:  2019-04-20       Impact factor: 2.378

3.  The Utility of Liver Biopsy in the Evaluation of Liver Disease and Abnormal Liver Function Tests.

Authors:  Ali Khalifa; David N Lewin; Roula Sasso; Don C Rockey
Journal:  Am J Clin Pathol       Date:  2021-07-06       Impact factor: 2.493

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.